Related Experiment Video
Updated: Dec 21, 2025
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Tirofiban Protocol Protects Against Delayed Cerebral Ischemia: A Case-Series Study
Mario Zanaty1, Carlos Osorno-Cruz1, Stefano Byer2
1Department of Neurosurgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa.
Background:
There has not been any effective prophylaxis for delayed cerebral ischemia delayed cerebral ischemia (DCI) since the introduction of nimodipine. Platelet inhibition may reduce the risk by preventing the formation of microthrombi. Tirofiban has been used as a single monotherapy bridge given its safety profile and controlled platelet inhibition.
Objective:
To assess the risk of DCI in aneurysmal subarachnoid hemorrhages (aSAH) patients treated with the tirofiban protocol.
Methods:
aSAH patients between December 2010 and March 2019 who were treated with stent assisted coiling or flow-diverting device were started on a continuous tirofiban infusion protocol and were compared with patients who underwent coil embolization without antiplatelet therapy. Safety analysis was performed to assess DCI, hemorrhagic, and ischemic events.
Results:
A total of 21 patients were included in the tirofiban series and 81 in the control group. There was no statistical difference in age, gender, Hunt-Hess grade, and Fisher scale between the 2 groups except for a higher Fisher grade II in the tirofiban group. Multivariate analysis revealed tirofiban to reduce the risk of vasospasm by 72 percent (OR .28, P = .03), without affecting the risk of hemorrhagic complications (OR = 0.50, P = .26). Tirofiban reduced the risk of symptomatic stroke endovascular procedure but it did not reach significance (P = .06). DCI, older age, and postprocedural symptomatic stroke were significant predictors of mortality. Tirofiban reduced the mortality risk, but this association was not statistically significant.
Conclusion:
The tirofiban protocol in aSAH patients reduces the risk of DCI without conferring additional risks. This supports previous findings were antiplatelet therapy reduced DCI in human and animal models.
Insights
Tirofiban effectively reduces the risk of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage. This platelet inhibition strategy offers a promising prophylaxis without increasing hemorrhagic complications.
Area of Science:
- Neurology
- Neurosurgery
- Pharmacology
Background:
- Delayed cerebral ischemia (DCI) remains a significant complication following aneurysmal subarachnoid hemorrhage (aSAH) with limited effective prophylactic options beyond nimodipine.
- Platelet inhibition presents a potential strategy to mitigate DCI by preventing microthrombus formation.
- Tirofiban, with its established safety profile and controlled platelet inhibition, has been explored as a monotherapy bridge for DCI prophylaxis.
Purpose of the Study:
- To evaluate the efficacy and safety of a tirofiban infusion protocol in reducing the risk of DCI in patients with aSAH.
- To compare DCI rates and associated complications in aSAH patients treated with tirofiban versus those without antiplatelet therapy.
Main Methods:
- A retrospective analysis of aSAH patients treated between December 2010 and March 2019.
- Patients treated with stent-assisted coiling or flow-diverting devices received a continuous tirofiban infusion protocol.
- Comparison with a control group undergoing coil embolization without antiplatelet therapy, with safety analysis for DCI, hemorrhagic, and ischemic events.
Main Results:
- The tirofiban group (21 patients) showed a significant 72% reduction in the risk of vasospasm compared to the control group (81 patients).
- Tirofiban did not increase the risk of hemorrhagic complications and showed a trend towards reducing symptomatic stroke risk.
- While DCI, older age, and postprocedural stroke predicted mortality, tirofiban demonstrated a non-significant trend in reducing mortality risk.
Conclusions:
- The tirofiban protocol in aSAH patients effectively reduces the risk of DCI without introducing additional safety concerns.
- Findings support the role of antiplatelet therapy, specifically tirofiban, in DCI prophylaxis, aligning with previous experimental and clinical evidence.
